SINGAPORE (May 21): Bruno de Pampelonne, chairman of Tikehau Investment Management, admits he is not a doctor; neither does his firm have in-house healthcare experts. However, that will not deter the former Merrill Lynch banker from making big bets on early-stage medical technology and life sciences companies.

Just recently, Tikehau IM partnered with SPRIM Ventures to launch a US$50 million ($67 million) healthcare venture capital fund called TKS1, which plans to push the boundaries in medical prediction, diagnosis and monitoring. The fund will allocate between US$500,000 and US$5 million to each startup, with the aim of producing faster and cheaper therapeutics.

So far, TKS1 has seeded five companies, most of which are based in Singapore. Some of these were previously seeded by medical and scientific consultancy firm SPRIM, the parent entity of SPRIM Ventures.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook